相关实验视频

Updated: Feb 24, 2026

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

了解生物标志物了解IgA驱动的自身免疫和纤维性疾病药物开发的第一课程

Myrthe Alexandra Maria van Delft^1,2,3,4, Aleksandra Cegiel¹, Marjolein van Egmond^3,4,5

¹JJP Biologics, Warsaw, Poland.

Cambridge prisms. Precision medicine

|February 23, 2026

概括

精准医学通过使用生物标志物进行向治疗来推进患者护理. 这项研究引入了一种新的策略,用于在IgA驱动疾病的早期发育中识别生物标志物,改善患者选择并降低成本.

科学领域:

生物医学研究的研究.
翻译医学是一种翻译医学.
药物基因组学药物基因组学

背景情况:

由人类基因组项目加速的个性化医学在癌症治疗中使用生物标志物 (例如,KRAS,HER2/3).
由于识别系统生物标志物的挑战,对炎症疾病的伴随诊断的临床采用滞后.
早期识别和整合生物标志物对于患者分层和有效的临床开发至关重要.

研究的目的:

在IgA驱动的自身免疫和纤维性疾病中选择最佳治疗点的替代策略.
突出早期生物标志物识别对于临床开发中的患者分层的重要性.
展示一种新的方法,用于在炎症条件下开发伴随诊断.

主要方法:

基于自身抗原特异性检测,分析生物通路以确定潜在的治疗点.
利用自身抗体血清水平作为IgA介导疾病患者选择的生物标志物.
在IgA驱动的自身免疫和纤维性疾病中选择抗CD89对手的策略的应用.

主要成果:

拟议的方法有助于在临床开发开始之前确定最佳的治疗点.
基于生物标志物的早期患者分层减少了研究所需的患者数量,并降低了开发成本.
这一策略将包括不响应患者的风险降至最低,从而避免不良事件.

结论:

在开发管道的早期确定生物标志物对于高效和成本效益的临床试验至关重要.
描述的策略为选择IgA介导的自身免疫和纤维性疾病的适当目标和患者群体提供了一种新的方法.
这种方法增强了伴随诊断的发展,并促进了以患者为中心的炎症疾病治疗方法.

关键词:

CD89 CD89 CD89 CD89 CD89 CD89 CD89 CD89 CD89 CD89 CD89 CD89 在 IgA A 里面.这是自抗体的自抗体.生物标志物生物标志物个性化医疗是个性化的医疗.

更多相关视频

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...